Clinical Trials

14 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × Plasma cell × Clear all
NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Celgene

Completed
1,149 enrolled
GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02921802 2022-06-14

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Celgene

Completed
4,626 enrolled
Classical hematologyMyeloidOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myelodysplastic Syndromes, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT02922543 2022-06-14

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Celgene

Completed
361 enrolled
Classical hematologyOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis